Avandia RECORD Study Re-Analysis To Get FDA Committee Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Two FDA panels will jointly review an independent “re-adjudication” of GlaxoSmithKline’s RECORD study of Avandia’s cardiovascular risk; 12 of 33 panel members voted to withdraw the drug when they considered the RECORD data in 2010.